Biogen’s stock rose 1% Thursday, after Europe’s pharmaceutical regulator issued a positive opinion on the Alzheimer’s disease ...

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...

The European Union's drugs regulator on Thursday recommended approval of Eisai and Biogen's Leqembi for some patients with ...

The CHMP renders a positive opinion recommending approval for BIIB and Eisai's Leqembi for treating early Alzheimer's disease ...

Trace Neuroscience, which launched this week with $101 million, benefited from last year’s approval of Qalsody. Its CEO spoke ...

Wolfe Research argues that despite a near-term impact, large-cap U.S. pharma stocks are largely immune from the anti-chronic ...

The European Union's drugs regulator on Thursday said it recommends approval of Eisai and Biogen's Leqembi in patients with ...

Citigroup initiated coverage on shares of Biogen (NASDAQ:BIIB – Get Free Report) in a report issued on Thursday, MarketBeat ...

Roche’s Evrysdi (risdiplam) is the market leader among the drugs for spinal muscular atrophy (SMA). Biogen’s Spinraza ...

Deep-pocketed investors have adopted a bearish approach towards Biogen BIIB, and it's something market players shouldn't ...

Los Angeles Capital Management LLC bought a new stake in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) in the third ...

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...